drugset / Trial / NCT00960804
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves
Timeline
- Start
- 2010-02-15
- Primary completion
- 2010-11-11
- Completion
- 2010-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tanezumab | Monoclonal antibody | 5 mg | Intravenous |
| Subject | Tanezumab | Monoclonal antibody | 10 mg | Intravenous |